Recruiting
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis - IM011-1105
Opdateret:
22 juli, 2024
|
ClinicalTrials.gov
Køn
Aldersinterval
Beliggenhed(er)
Recruiting
Inclusion Criteria: - Have been diagnosed with plaque psoriasis by a dermatologist - Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) - Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes Exclusion Criteria: - Currently participating in an interventional clinical trial (does not include observational registry or study)
Hvis du vil rapportere en bivirkning, kan du indberette direkte til Lægemiddelstyrelsen via hjemmesiden www.meldenbivirkning.dk
Vi anbefaler at du også kontakter BMS for at rapportere bivirkninger.
Bivirkninger og andre rapporterbare begivenheder er defineret her
Rapporter bivirkninger eller klager over produktkvalitet: Medicinsk information
466-DK-2200001